{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:12:08Z","timestamp":1761988328869,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jcpo.2021.100279","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T13:15:41Z","timestamp":1614345341000},"page":"100279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-6073","authenticated-orcid":false,"given":"Boris","family":"Rachev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Wilking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela","family":"Kobelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-2850","authenticated-orcid":false,"given":"Federico","family":"Spandonaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjana","family":"Rajer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8402-1797","authenticated-orcid":false,"given":"Alexander","family":"Roediger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00ebl","family":"Normand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2021.100279_bib0005","unstructured":"Italy used 5 indications in the adaptation: melanoma, 1L NSCLC, head and neck, bladder cancer, and renal cell carcinoma. This was due to the differences in the marketing authorization (EMA) and reimbursement approval (AIFA) timelines."},{"key":"10.1016\/j.jcpo.2021.100279_bib0010","unstructured":"The HIP model was developed by Adelphi Values under the sponsorship and methodological supervision of the Center for Observational and Real-world Evidence at Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA."},{"key":"10.1016\/j.jcpo.2021.100279_bib0015","unstructured":"Includes Pembrolizumab, Durvalumab, Atezolizumab, Nivolumab, and Avelumab."},{"year":"2019","series-title":"Comparator Report on Cancer in Europe 2019 \u2013 Disease Burden, Costs and Access to Medicines","author":"Hofmarcher","key":"10.1016\/j.jcpo.2021.100279_bib0020"},{"key":"10.1016\/j.jcpo.2021.100279_bib0025","series-title":"Advances, Complexity and Cost","first-page":"1","article-title":"Global oncology trends 2017","author":"Aitken","year":"2017"},{"year":"2019","series-title":"One in Two Patients With Metastatic Melanoma Alive After Five Years With Combination Immunotherapy (ESMO 2019 Press Release)","author":"ESMO","key":"10.1016\/j.jcpo.2021.100279_bib0030"},{"year":"2019","series-title":"Outlook on the Global Oncology\/Cancer Drugs Market to 2025","author":"Business Wire","key":"10.1016\/j.jcpo.2021.100279_bib0035"},{"key":"10.1016\/j.jcpo.2021.100279_bib0040","unstructured":"IMS and Cowen and Co. data."},{"key":"10.1016\/j.jcpo.2021.100279_bib0045","series-title":"PD-1\/PD-L1 Market Model Update - US Estimates","first-page":"1","author":"Scala","year":"2017"},{"issue":"9","key":"10.1016\/j.jcpo.2021.100279_bib0050","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/jama.2020.1012","article-title":"Changes in list prices, net prices, and discounts for branded drugs in the US, 2007-2018","volume":"323","author":"Hernandez","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jcpo.2021.100279_bib0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti CTLA 4 treatment (CheckMate 037): a randomised, controlled, open label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet"},{"issue":"10105","key":"10.1016\/j.jcpo.2021.100279_bib0060","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open label phase 3 study (KEYNOTE 006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jcpo.2021.100279_bib0065","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small cell lung Cancer","author":"Paz Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2021.100279_bib0070","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"375","key":"10.1016\/j.jcpo.2021.100279_bib0075","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for pd l1 positive non-small cell lung cancer","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"373","key":"10.1016\/j.jcpo.2021.100279_bib0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous cell non-small cell lung cancer","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2021.100279_bib0085","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ijc.28966","article-title":"Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer","author":"Zhang","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.jcpo.2021.100279_bib0090","article-title":"KEYNOTE 048: phase III study of first line pembrolizumab (P) for recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC)","volume":"29","author":"Burtness","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jcpo.2021.100279_bib0095","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous cell carcinoma of the head and neck","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2021.100279_bib0100","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second line therapy for advanced urothelial carcinoma","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2021.100279_bib0105","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal cell carcinoma","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2021.100279_bib0110","unstructured":"Due to the availability of more recent data, as well as the increase in physicians\u2019 experience in using anti\u2013PD-1\/PD-L1 agents, in their 2019 model updates, countries preferred to select the default trials based on the most commonly used treatment within a specified indication."},{"key":"10.1016\/j.jcpo.2021.100279_bib0115","unstructured":"Due to the objectives of the HIP \u2013 i.e., that overall class impact accuracy is more desirable than the high precision estimation of key parameters such as time-dependent hazard rates via piecewise curve fitting, an exponential distribution was selected for the SOC curves as the simplest parametric model, as it incorporates a hazard function that is constant over time. The treatment effect is measured as a hazard ratio. After receiving expert validation of the approach taken, an exponential distribution was deemed the most appropriate method for SOC survival curve extrapolation. The accuracy improvement obtained from using more advanced extrapolation methods would be offset by underlying assumptions which would still be present, irrespective of the methods used for extrapolation."},{"year":"2017","series-title":"NICE DSU TECHNICAL SUPPORT DOCUMENT 19: Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review","author":"Woods","key":"10.1016\/j.jcpo.2021.100279_bib0120"},{"year":"2005","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","key":"10.1016\/j.jcpo.2021.100279_bib0125"},{"key":"10.1016\/j.jcpo.2021.100279_bib0130","doi-asserted-by":"crossref","unstructured":"Peter J. Neumann, Gillian D. Sanders, Louise B. Russell, Joanna E. Siegel, Theodore G. Ganiats, (Eds.), Cost-Effectiveness in Health and Medicine, 2016, November 536 Pages.","DOI":"10.1093\/acprof:oso\/9780190492939.001.0001"},{"issue":"1","key":"10.1016\/j.jcpo.2021.100279_bib0135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.jcpo.2021.100279_bib0140","unstructured":"HIP country teams were comprised of country and headquarters MSD teams, country experts and consultants."},{"key":"10.1016\/j.jcpo.2021.100279_bib0145","article-title":"Special session","volume":"31","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"year":"2017","series-title":"Cancer Incidence Projections in Belgium 2015-2025","author":"Registry","key":"10.1016\/j.jcpo.2021.100279_bib0150"},{"year":"2020","series-title":"Belgian Cancer Registry, Source","key":"10.1016\/j.jcpo.2021.100279_bib0155"},{"year":"2015","series-title":"Cancer Registry of Republic of Slovenia","author":"Cancer in Slovenia","key":"10.1016\/j.jcpo.2021.100279_bib0160"},{"issue":"3","key":"10.1016\/j.jcpo.2021.100279_bib0165","first-page":"1","article-title":"Health system review. Health systems in transition","volume":"18","author":"Albreht","year":"2016","journal-title":"Slovenia"},{"year":"2018","series-title":"Active Ageing Strategy","key":"10.1016\/j.jcpo.2021.100279_bib0170"},{"year":"2014","series-title":"GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]","author":"Ferlay","key":"10.1016\/j.jcpo.2021.100279_bib0175"},{"year":"2019","series-title":"I Numeri Del Cancro In Italia","author":"AIRTUM","key":"10.1016\/j.jcpo.2021.100279_bib0180"},{"key":"10.1016\/j.jcpo.2021.100279_bib0185","first-page":"41","volume":"Volume 129","author":"Hofmarcher","year":"2020"},{"issue":"12","key":"10.1016\/j.jcpo.2021.100279_bib0190","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.21037\/jtd.2017.10.152","article-title":"Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed","volume":"9","author":"Tu","year":"2017","journal-title":"J. Thorac. Dis."},{"issue":"March 01","key":"10.1016\/j.jcpo.2021.100279_bib0195","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Brahmer updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non\u2013small-Cell lung Cancer With PD-L1 tumor proportion score of 50% or greater","volume":"37:7","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538321000102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538321000102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:07:24Z","timestamp":1761988044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538321000102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":39,"alternative-id":["S2213538321000102"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2021.100279","relation":{},"ISSN":["2213-5383"],"issn-type":[{"type":"print","value":"2213-5383"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2021.100279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100279"}}